-+ 0.00%
-+ 0.00%
-+ 0.00%

Inovio Pharmaceuticals' Partner For VGX-3100 In China, ApolloBio, Announces Topline Results From Its Pivotal Phase 3 Trial Of VGX-3100; Trial Met Its Predefined Primary Efficacy Endpoint And Demonstrated An Overall Favorable Safety And Tolerability Profile

Benzinga·05/21/2026 20:09:22
Listen to the news

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its partner for VGX-3100 in China, ApolloBio, announced positive topline results from its pivotal Phase 3 trial of VGX-3100, INOVIO's investigational DNA immunotherapy being developed as a potential treatment for cervical dysplasia. The trial successfully met its predefined primary efficacy endpoint and demonstrated an overall favorable safety and tolerability profile. ApolloBio plans to use the results from the study to support a future regulatory submission of VGX-3100 in China.